How it Works
Fill out a quick medical intake form
Consultation -Licensed provider reviews and creates your custom plan
Medication ships directly to your door
Get ongoing support
Before & After Success Stories
Semaglutide Program Options
5 Week Starter Program - $299
-
Includes GLP-1 medication (Semaglutide)
- Covers 5 weeks of treatment at 0.25 mg - 0.5 mg weekly dosing
- All medication and supplies shipped directly to your home
- Ongoing provider support included throughout your program
- No membership fees or automatic charges - one time payment only
8 Week Core Program - $399
-
Includes GLP-1 medication (Semaglutide)
-
Covers 8 weeks of treatment at 0.25 mg - 1 mg weekly dosing
-
All medication and supplies shipped directly to your home
-
Ongoing provider support included throughout your program
-
No membership fees or automatic charges - one time payment only
12 Week Transform Program - $599
-
Includes GLP-1 medication (Semaglutide)
-
Covers 12 weeks of treatment at 0.25 mg - 1 mg weekly dosing
-
All medication and supplies shipped directly to your home
-
Ongoing provider support included throughout your program
-
No membership fees or automatic charges - one time payment only
FAQ
What are compounded medications? We offer compounded Semaglutide and Tirzepatide, featuring the same active ingredients as the commercial products Wegovy® and Mounjaro®/Zepbound™, respectively. Disclaimer: Compounded medications are not FDA-approved and should be discussed with your healthcare provider to understand the specific risks and benefits. While compounded in licensed pharmacies, these medications may not have the same safety and efficacy profiles as commercially available drugs.
Who is eligible for these medications? Adults with a BMI of 30 kg/m² or greater (obesity) Adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
How much weight can I expect to lose? For Semaglutide, the STEP trials demonstrated an average weight loss of around 15% of body weight over 68 weeks in adults with obesity or overweight with weight-related conditions. Participants also saw improvements in cardiovascular health markers and glycemic control. For Tirzepatide, the SURPASS trials indicated even greater weight loss, with participants losing up to 20% of their body weight over 72 weeks. Additionally, Tirzepatide showed improvements in insulin sensitivity, lipid profiles, and other metabolic health markers. These results highlight the potential for substantial weight reduction and overall health improvement with both medications. It is important to discuss with your healthcare provider to determine the best option for your individual needs.
What is the difference between Semaglutide and Tirzepatide? Semaglutide, a GLP-1 receptor agonist, promotes weight loss by increasing insulin secretion, reducing appetite, and slowing gastric emptying, resulting in effective appetite control and calorie reduction. Tirzepatide, with its dual action on GIP and GLP-1 receptors, not only enhances these effects but also significantly improves insulin sensitivity. This dual mechanism offers a more robust approach to weight loss, potentially leading to greater and more sustained weight reduction compared to Semaglutide.
What are potential side effects of these medications? Common side effects include nausea, vomiting, diarrhea, and constipation, while less common effects are abdominal pain, indigestion, and fatigue. Serious side effects, though rare, may include pancreatitis, gallbladder issues such as gallstones, kidney problems, and allergic reactions. Discuss these potential side effects with your healthcare provider before starting treatment.
How are these medications taken? Both Semaglutide and Tirzepatide are taken as subcutaneous injections, administered once a week. These injections can be self-administered in the abdomen, thigh, or upper arm. It is important to follow your healthcare provider's instructions on the proper injection technique and schedule.